PRIMARY HYPERPARATHYROIDISM AND SERUM CALCIUM IN BREAST CANCER PATIENTS EVALUATED FOR LOW BONE MASS--A SINGLE CENTER EXPERIENCE/PRIMARNI HIPERPARATIREOIDIZAM I SERUMSKI KALCIJ U BOLESNICA S RAKOM DOJKE TIJEKOM PROCJENE NISKE KOSTANE MASE--ISKUSTVO JEDNOG CENTRA

The bone health guidelines for breast cancer (BC) patients recommend bone mineral density (BMD) testing. Patients with low BMD and elevated serum calcium levels (SCLs) are further evaluated for primary hyperparathyroidism (PHPT). We aimed to determine the prevalence of PHPT in treated BC patients wi...

Full description

Saved in:
Bibliographic Details
Published in:Acta clinica Croatica (Tisak) 2021-12, Vol.60 (4), p.617
Main Authors: Punda, Marija, Ovcaricek, Petra Petranovic, Tabain, Anita, Koopmans, Klaas Pieter, Alfer, Gabriela, Jukic, Tomislav, Frobe, Ana
Format: Article
Language:English
Subjects:
Bones
Breast cancer
Calcium, Dietary
Care and treatment
Complications and side effects
Density
Diagnosis
Health aspects
Hyperparathyroidism
Measurement
Prognosis
Risk factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The bone health guidelines for breast cancer (BC) patients recommend bone mineral density (BMD) testing. Patients with low BMD and elevated serum calcium levels (SCLs) are further evaluated for primary hyperparathyroidism (PHPT). We aimed to determine the prevalence of PHPT in treated BC patients with low BMD and analyze the association of SCLs with histopathologic tumor features and cancer treatment. This retrospective study included postmenopausal BC patients examined at Osteoporosis Clinic between 2013 and 2020. Clinical and BMD data were collected from patient medical records. Patients with biochemical suspicion of PHPT underwent standard parathyroid imaging procedures. Nine out of 137 (6.6%) patients were diagnosed with PHPT; 8/9 patients underwent parathyroidectomy and one patient was advised to follow-up. Among the rest of 128 non-PHPT patients, higher SCLs showed a trend of positive association with higher tumor grade and axillary lymph node involvement, and received immunotherapy, although without statistical significance. We found a higher prevalence of PHPT in treated BC patients compared to the general population. Higher SCLs show a trend of positive correlation with some more aggressive histopathologic tumor features and with immunotherapy. The results of this study suggest that assessment of SCLs should be routinely performed to rule out PHPT in treated BC patients with low BMD. Key words: Primary hyperparathyroidism; Serum calcium; Breast cancer; Bone mineral density; Cancer treatment Smjernice o kostanom zdravlju za bolesnice s rakom dojke (RD) preporucuju ispitivanje mineralne gustoce kostiju (bone mineral density, BMD). U bolesnica s niskom vrijednosti BMD-a i povisenom razinom kalcija u serumu (RKS) dodatno se procjenjuje primarni hiperparatireoidizam (PHPT). Cilj je bio utvrditi ucestalost PHPT-a u lijecenih bolesnica s RD i snizenom vrijednosti BMD-a te analizirati povezanost RKS s histopatoloskim znacajkama tumora i onkoloskim lijecenjem. Retrospektivna studija obuhvatila je postmenopauzalne bolesnice s RD koje su pregledane u Ambulanti za osteoporozu izmedu 2013. i 2020. godine. Klinicki podaci i podaci o BMD prikupljeni su iz medicinske dokumentacije. Bolesnice s biokemijskom sumnjom na PHPT podvrgnute su standardnim postupcima snimanja paratireoidnih zlijezda. U devet od 137 (6,6%) bolesnica dijagnosticiran je PHPT; 8/9 bolesnica podvrgnuto je paratireoidektomiji, a jednoj je bolesnici savjetovano pracenje. U ostalih 128 bolesnica
ISSN:0353-9466
DOI:10.20471/acc.2021.60.04.08